The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
BUSINESS
Dispensing Pharmacies Worried about Reversal of Delivery and NHI Prices Following Re-Pricing of Gilead’s “Huge Seller” Hep C Drugs
Gilead Sciences’ oral chronic hepatitis C treatments Harvoni (ledipasvir + sofosbuvir) and Sovaldi (sofosbuvir) will be hit with large reductions in their NHI prices under the “huge seller” re-pricing rule in this April’s NHI price revision. An official in charge…
To read the full story
BUSINESS
- Drug Makers Weigh Withdrawal of Unprofitable Drugs, Generic and Innovative Players Alike: Poll
March 11, 2025
- Daiichi Curbs Enhertu Shipments on Spiking Demand in Japan
March 11, 2025
- Amitiza Notches Triple Crowns in Hospital Doctor Promotion in January: Intage
March 11, 2025
- Japan Drug Makers See Varied Impact from 2025 Revision, Foreign Firms Take Hit: Poll
March 10, 2025
- Astellas, Yaskawa Electric to Form JV for Cell Therapy Production
March 10, 2025
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…